Literature DB >> 9833597

Relationships among liver and kidney volumes, lean body mass and drug clearance.

S Nawaratne1, J E Brien, E Seeman, R Fabiny, J Zalcberg, W Cosolo, P Angus, D J Morgan.   

Abstract

AIMS: To determine whether lean body mass (LBM), a possible surrogate of liver and kidney volumes, correlates with hepatic and renal drug clearances.
METHODS: Twenty-one disease-free patients with a history of cancer and with normal hepatic and renal function were studied. Salivary pharmacokinetics of oral antipyrine (1200 mg) and 24 h creatinine clearance were determined following the determination of LBM by dual energy X-ray absorptiometry and the determination of liver and kidney volumes by helical CT scanning.
RESULTS: Liver volume correlated with LBM (r2=0.21, P=0.04), body surface area (BSA) (r2=0.54, P<0.001), and total body weight (TBW) (r2=0.61, P<0.001). Kidney volume correlated with LBM (r2=0.49, P<0.001), BSA (r2=0.43, P=0.002) and TBW (r2=0.24, P=0.03). Stepwise multiple regression analysis, incorporating the independent variables of age, height, weight, sex, BSA, LBM, alcohol consumption, smoking status and liver volume and the dependent variable antipyrine clearance, indicated that LBM was the only independent correlate of antipyrine clearance. A stepwise multiple regression analysis with kidney volume in the independent variables, and creatinine clearance as dependent variable, showed that kidney volume and age were the only independent correlates of creatinine clearance. A nomogram using serum creatinine and LBM was comparable with the Cockcroft and Gault nomogram in calculating creatinine clearance.
CONCLUSIONS: Of the anthropometric variables tested, LBM was the only determinant of antipyrine clearance, but this was not due to a relationship between LBM and liver volume. By contrast, the relationship between creatinine clearance and LBM appeared to be due to a relationship between LBM and kidney volume.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833597      PMCID: PMC1873697          DOI: 10.1046/j.1365-2125.1998.00812.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.

Authors:  J E Sharer; S A Wrighton
Journal:  Drug Metab Dispos       Date:  1996-04       Impact factor: 3.922

3.  Energy and the maintenance of the body cell mass.

Authors:  F D Moore
Journal:  JPEN J Parenter Enteral Nutr       Date:  1980 May-Jun       Impact factor: 4.016

4.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

5.  Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

Authors:  B Bach; J M Hansen; J P Kampmann; S N Rasmussen; L Skovsted
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  Should clearance be normalised to body surface or to lean body mass?

Authors:  T H Hallynck; H H Soep; J A Thomis; J Boelaert; R Daneels; L Dettli
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

7.  High-pressure liquid chromatographic analysis of antipyrine in small plasma samples.

Authors:  L Shargel; W M Cheung; A B Yu
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

8.  Antipyrine disposition and liver size in the elderly.

Authors:  C G Swift; M Homeida; M Halliwell; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

9.  Prediction of creatinine clearance from serum creatinine concentration based on lean body mass.

Authors:  T Hallynck; H H Soep; J Thomis; J Boelaert; R Daneels; J P Fillastre; F De Rosa; E Rubinstein; M Hatala; J Spousta; L Dettli
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

10.  Liver size in evaluating drug metabolizing capacity in man.

Authors:  H Pirttiaho
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-06
View more
  21 in total

Review 1.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Authors:  Kathleen A Meeske; Lingyun Ji; David R Freyer; Paul Gaynon; Kathleen Ruccione; Anna Butturini; Vassilios I Avramis; Stuart Siegel; Yousif Matloub; Nita L Seibel; Richard Sposto
Journal:  Pediatr Blood Cancer       Date:  2015-07-14       Impact factor: 3.167

3.  Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.

Authors:  Akira Okada; Hidetaka Ushigome; Misaki Kanamori; Aya Morikochi; Hidefumi Kasai; Tadashi Kosaka; Takatoshi Kokuhu; Asako Nishimura; Nobuhito Shibata; Keizo Fukushima; Norio Yoshimura; Nobuyuki Sugioka
Journal:  Eur J Clin Pharmacol       Date:  2017-06-15       Impact factor: 2.953

4.  Prediction of drug clearance in children from adults: a comparison of several allometric methods.

Authors:  Iftekhar Mahmood
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.

Authors:  Jennifer H Martin; Mohamed Saleem; David Looke
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

6.  Determinants and functional significance of renal parenchymal volume in adults.

Authors:  Samuel Johnson; Rahul Rishi; Andreea Andone; Wassim Khawandi; Jafar Al-Said; Nana Gletsu-Miller; Edward Lin; Deborah A Baumgarten; W Charles O'Neill
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 8.237

7.  Low skeletal muscle is associated with toxicity in patients included in phase I trials.

Authors:  Sophie Cousin; A Hollebecque; S Koscielny; O Mir; A Varga; V E Baracos; J C Soria; S Antoun
Journal:  Invest New Drugs       Date:  2013-12-17       Impact factor: 3.850

8.  The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.

Authors:  Satoshi Sobue; Keith Tan; Gary Layton; Violette Leclerc; Angelika Weil
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

9.  Donor Age, Donor-Recipient Size Mismatch, and Kidney Graft Survival.

Authors:  Fanny Lepeytre; Catherine Delmas-Frenette; Xun Zhang; Stéphanie Larivière-Beaudoin; Ruth Sapir-Pichhadze; Bethany J Foster; Héloïse Cardinal
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237

10.  Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants.

Authors:  Rishi Jain; Elizabeth Handorf; Vipin Khare; Matthew Blau; Yana Chertock; Michael J Hall
Journal:  Oncologist       Date:  2019-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.